Fig. 5From: miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway MiR-634 enhances the sensitivity for chemotherapy. By regulation of Cyclin D1 and the Ras-MAPK pathway, miR-634 overexpression may affect the cell cycle profile and apoptosis. Furthermore, repression of the Ras-MAPK pathway, which inhibits several pro-apoptotic factors (e.g. Bad [55], BimEL [56, 57]), can indirectly sensitize ovarian tumors to chemotherapeutics, such as cisplatin/carboplatin (Pt) and doxorubicin (dox)Back to article page